IBRX vs JANX
IBRX: ImmunityBio develops innovative immunotherapies and cell-based cancer vaccines that leverage its Cancer BioShield platform to treat oncology and infectious disease patients. JANX: Janux Therapeutics is a clinical-stage biotech developing next-generation, tumor-activated bispecific immunotherapies to improve the safety and efficacy of cancer and autoimmune treatments.
Side-by-side fundamentals
| Metric | IBRX | JANX | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $7.60 | $16.52 | |
| Market cap as of 2026-08-12 | $8.1B | $1.0B | |
| PEG as of 2026-08-12 | -0.08 | n/a | |
| Net margin as of 2026-08-12 | -598.6% | -294.4% | JANX higher |
| Gross margin as of 2026-08-12 | +99.3% | n/a | |
| Operating margin as of 2026-08-12 | -151.9% | -421.5% | IBRX higher |
| ROE as of 2026-08-12 | -193.3% | -10.8% | JANX higher |
| ROA as of 2026-08-12 | -172.9% | -10.1% | JANX higher |
| Debt / equity as of 2026-08-12 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-12 | +192.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +678.6% | n/a | |
| Beta as of 2026-08-12 | 0.07 | 2.39 | |
| 1-year return as of 2026-08-11 close | +207.7% | -27.1% | IBRX higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.